Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Depreciation & Amortization (CF) (2019 - 2025)

VYNE Therapeutics (VYNE) has disclosed Depreciation & Amortization (CF) for 5 consecutive years, with $6000.0 as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Depreciation & Amortization (CF) changed N/A year-over-year to $6000.0, compared with a TTM value of $12000.0 through Dec 2025, changed N/A, and an annual FY2025 reading of $23000.0, up 475.0% over the prior year.
  • Depreciation & Amortization (CF) was $6000.0 for Q2 2025 at VYNE Therapeutics, roughly flat from $6000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $171000.0 in Q3 2022 and bottomed at -$155000.0 in Q4 2022.
  • Average Depreciation & Amortization (CF) over 3 years is $19300.0, with a median of $26500.0 recorded in 2021.
  • Peak annual rise in Depreciation & Amortization (CF) hit 510.71% in 2022, while the deepest fall reached 696.15% in 2022.
  • Year by year, Depreciation & Amortization (CF) stood at $26000.0 in 2021, then plummeted by 696.15% to -$155000.0 in 2022, then surged by 103.87% to $6000.0 in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for VYNE at $6000.0 in Q2 2025, $6000.0 in Q1 2025, and -$155000.0 in Q4 2022.